INBRAIN Neuroelectronics, a brain-computer interface therapeutics company developing graphene-based neural technologies, has announced a strategic partnership with Microsoft to harness agentic artificial intelligence (AI) through Microsoft’s cloud and data infrastructure. The collaboration aims to advance real-time precision neurology and next-generation brain-computer interface (BCI) therapeutics.
Using Microsoft’s Azure AI capabilities—including time-series large language models and advanced analytics—the partnership will enable INBRAIN’s intelligent neural platform to learn and adapt to individual patient signals in real time. This agentic AI approach, where systems act autonomously on live data, could revolutionize how neurological disorders such as Parkinson’s disease, epilepsy, and psychiatric or memory disorders are monitored and treated through closed-loop precision interventions.
“Our vision is to create the most intelligent, autonomous, and personalized interface between the nervous system and AI,” said Carolina Aguilar, CEO and Co-Founder of INBRAIN Neuroelectronics. “By collaborating with Microsoft, we’re combining our graphene neural technology with one of the world’s most powerful AI ecosystems, moving toward a future where brain-computer interfaces can understand and respond to the nervous system in real time.”
Clare Barclay, President of Enterprise and Industry, EMEA at Microsoft, added that the partnership represents “the next frontier of AI,” bringing together neuroscience, bioelectronics, and AI to improve neurological health globally.
Built on graphene—a highly conductive, biocompatible material—INBRAIN’s platform integrates decoding and modulation with agentic AI to enable personalized, data-driven modulation of neural circuits, potentially opening the door to a new era of organ therapeutics. The collaboration also aligns with Microsoft’s commitment to advancing responsible healthcare AI, cognitive modeling, and ethical data use in neurotechnology.
Click here to read the original news story.